Avalo Launches Long-Acting Anti-IL-1β Candidate with IND Planned in H1 2027
AVTX•Avalo Therapeutics announced AVTX-010, a long-acting next-generation anti-IL-1β antibody for hidradenitis suppurativa and other inflammatory diseases, with an IND submission planned for H1 2027. The company completed transformational financing in May and will advance its Phase 2 asset, abdakibart, into a pivotal Phase 3 registrational study.
1. Pipeline Expansion
Avalo Therapeutics has introduced AVTX-010, an engineered anti-IL-1β monoclonal antibody designed for extended dosing intervals. The candidate targets hidradenitis suppurativa and additional immune-mediated inflammatory disorders while potentially strengthening the company’s intellectual property position.
2. Strategic Rationale
AVTX-010 builds on positive Phase 2 topline data from abdakibart in hidradenitis suppurativa and leverages advanced molecular engineering to reduce dosing frequency. The long-acting profile is intended to enhance physician preference, patient convenience, treatment adherence and overall experience in chronic inflammatory conditions.
3. Financing and Development Plans
Avalo completed transformational financing in May, bolstering resources for clinical programs. The company expects to submit an IND for AVTX-010 in the first half of 2027 and is moving abdakibart into a pivotal Phase 3 registrational program.
